{"id":428,"date":"2015-03-18T05:49:30","date_gmt":"2015-03-18T05:49:30","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=428"},"modified":"2021-07-24T12:56:25","modified_gmt":"2021-07-24T07:26:25","slug":"antibody-drug-conjugate-market-outlook-2015-report-in-market-now","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now","title":{"rendered":"Antibody-Drug Conjugate Market Outlook, 2015 Report in Market Now!"},"content":{"rendered":"<p><img decoding=\"async\" class=\"aligncenter  wp-image-429\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/assdd.png\" alt=\"assdd\" width=\"414\" height=\"237\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/03\/assdd.png 694w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2015\/03\/assdd-300x172.png 300w\" sizes=\"(max-width: 414px) 100vw, 414px\" \/><\/p>\n<blockquote>\n<p style=\"text-align: center;\"><span style=\"color: #000080;\"><strong>Launch of DelveInsight\u2019s Antibody-Drug Conjugate Report<\/strong><\/span><\/p>\n<\/blockquote>\n<p style=\"text-align: justify;\"><strong>DelveInsight\u2019s<\/strong> <strong>Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015<\/strong>, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives c<strong><img decoding=\"async\" class=\"  wp-image-430 alignright\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/dadadadadad.png\" alt=\"dadadadadad\" width=\"331\" height=\"266\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/03\/22083044\/dadadadadad.png 397w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2015\/03\/22083044\/dadadadadad-20x16.png 20w\" sizes=\"(max-width: 331px) 100vw, 331px\" \/><\/strong>ore information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company\u2019s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region.<\/p>\n<div><strong><strong>Around 253 ADCs in Oncology<\/strong><\/strong><\/div>\n<div>Antibody-Drug Conjugates are getting researched mostly for cancers. Cancer being the highest research area, there are 253 ADCs currently in pipeline. There are other companies which is also researching the ADC for different therapeutic areas like dermatology, immunology, women\u2019s health, gastrointestinal and ophthalmology.<\/p>\n<div align=\"justify\"><\/div>\n<div align=\"justify\">\n<div><strong>Four Potential ADCs in Phase III Pipeline\u00a0<\/strong><\/p>\n<div align=\"justify\">Companies are trying its already marketed ADC for different combinations and for different indications like Roche, Seattle Genetics conducting total 9 trials on their ADCs trastzumab emantisine and Brentuximab Vedotin. There are two new ADCs AstraZeneca\u2019s Moxetumomab Pasudotox and Pfizer\u2019s Inotuzumab Ozogamicin for Relapsed\/ Refractory Hairy Cell Leukemia and Acute Lymphoblastic Leukemia respectively.<\/div>\n<div align=\"justify\"><\/div>\n<div align=\"justify\"><\/div>\n<div align=\"justify\"><\/div>\n<div align=\"justify\"><strong>Report Pricing<\/strong><\/div>\n<div align=\"justify\">Single User License:\u00a0 3500 USD<\/div>\n<div align=\"justify\">Site License: 7000 USD<\/div>\n<div align=\"justify\">Global License: 10500 USD<\/div>\n<div align=\"justify\"><\/div>\n<div align=\"justify\"><em>For more information email us at info@delveinsight.com or visit us at www.delveinsight.com<\/em><\/div>\n<div align=\"justify\"><\/div>\n<div align=\"justify\"><\/div>\n<div style=\"text-align: center;\" align=\"justify\"><span style=\"color: #993366;\"><strong>Ask for Sample Pages now!<\/strong><\/span><\/div>\n<div style=\"text-align: center;\" align=\"justify\"><\/div>\n<div style=\"text-align: center;\" align=\"justify\">[contact-form][contact-field label=&#8217;Name&#8217; type=&#8217;name&#8217; required=&#8217;1&#8217;\/][contact-field label=&#8217;Email&#8217; type=&#8217;email&#8217; required=&#8217;1&#8217;\/][contact-field label=&#8217;Website&#8217; type=&#8217;url&#8217;\/][contact-field label=&#8217;Comment&#8217; type=&#8217;textarea&#8217; required=&#8217;1&#8217;\/][\/contact-form]<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Launch of DelveInsight\u2019s Antibody-Drug Conjugate Report DelveInsight\u2019s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[77,173,180,198,213,274,356,386,405,466,479,480,483,485,558,579],"industry":[17225],"therapeutic_areas":[17235,17228],"class_list":["post-428","post","type-post","status-publish","format-standard","hentry","category-articles","tag-antibody-drug-conjugate","tag-collaborations","tag-competitive-landscape","tag-cytotoxic-drug","tag-discovery","tag-global-market","tag-licensing-opportunities","tag-market-trends","tag-monoclonal-antibody","tag-pharma-company","tag-pipeline-coverage","tag-pipeline-coverage-and-competitive-landscape","tag-pipeline-outlook","tag-pipeline-reports","tag-technology-assessments","tag-track-your-closest-competitors","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Antibody-Drug Conjugate Market Outlook | DelveInsight<\/title>\n<meta name=\"description\" content=\"DelveInsight\u2019s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibody-Drug Conjugate Market Outlook | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"DelveInsight\u2019s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-03-18T05:49:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/assdd.png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antibody-Drug Conjugate Market Outlook | DelveInsight","description":"DelveInsight\u2019s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now","og_locale":"en_US","og_type":"article","og_title":"Antibody-Drug Conjugate Market Outlook | DelveInsight","og_description":"DelveInsight\u2019s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain.","og_url":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-03-18T05:49:30+00:00","article_modified_time":"2021-07-24T07:26:25+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/assdd.png","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now","url":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now","name":"Antibody-Drug Conjugate Market Outlook | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/assdd.png","datePublished":"2015-03-18T05:49:30+00:00","dateModified":"2021-07-24T07:26:25+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"DelveInsight\u2019s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-market-outlook-2015-report-in-market-now#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/assdd.png","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/assdd.png"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugate<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">cytotoxic drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Discovery<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Global Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">licensing opportunities<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">market trends<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">monoclonal antibody<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharma Company<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline coverage<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pipeline coverage and competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline Outlook<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">technology assessments<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Track your closest Competitors<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugate<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">cytotoxic drug<\/span>","<span class=\"advgb-post-tax-term\">Discovery<\/span>","<span class=\"advgb-post-tax-term\">Global Market<\/span>","<span class=\"advgb-post-tax-term\">licensing opportunities<\/span>","<span class=\"advgb-post-tax-term\">market trends<\/span>","<span class=\"advgb-post-tax-term\">monoclonal antibody<\/span>","<span class=\"advgb-post-tax-term\">Pharma Company<\/span>","<span class=\"advgb-post-tax-term\">Pipeline coverage<\/span>","<span class=\"advgb-post-tax-term\">pipeline coverage and competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">Pipeline Outlook<\/span>","<span class=\"advgb-post-tax-term\">Pipeline Reports<\/span>","<span class=\"advgb-post-tax-term\">technology assessments<\/span>","<span class=\"advgb-post-tax-term\">Track your closest Competitors<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 18, 2015","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 18, 2015 5:49 am","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=428"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/428\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=428"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=428"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}